113 related articles for article (PubMed ID: 9760148)
21. Mobilisation of haemopoietic progenitors in CML: a second course of intensive chemotherapy does not improve Ph-negativity in stem cell harvests.
Janssen JJ; van Rijn RS; van der Holt B; Schuurhuis GJ; Vellenga E; Verhoef GE; Ossenkoppele GJ; van den Berg E; Hagemeijer A; Släter R; Nieuwint AW; Cornelissen JJ
Bone Marrow Transplant; 2000 Jun; 25(11):1147-55. PubMed ID: 10849527
[TBL] [Abstract][Full Text] [Related]
22. Quality of IL-3 and G-CSF-mobilized peripheral blood stem cells in patients with early chronic phase CML.
Heinzinger M; Waller CF; Rosenstiel A; Scheid S; Burger KJ; Lange W
Leukemia; 1998 Mar; 12(3):333-9. PubMed ID: 9529127
[TBL] [Abstract][Full Text] [Related]
23. Safe mobilization of normal progenitors in advanced chronic myeloid leukemia with intensive chemotherapy and granulocyte-colony stimulating factor.
Morton J; Mollee P; Taylor K; Grigg A; Durrant S; Moore D; Rodwell R; Eliadis P; Hutchins C; Williams B; Seeley G; Wright S; Kelly C; Rentoul A; Iland H; Atkinson K; Januszewicz H; Bunce I; Bashford J; Stewart C; Taylor D
Leuk Res; 1999 Feb; 23(2):177-83. PubMed ID: 10071133
[TBL] [Abstract][Full Text] [Related]
24. A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia.
Dutcher JP; Morris EL; Gaynor B; Paietta E; Wiernik PH
Med Oncol; 2010 Sep; 27(3):728-35. PubMed ID: 19697165
[TBL] [Abstract][Full Text] [Related]
25. Mobilization of Philadelphia-negative peripheral blood progenitor cells with chemotherapy and rhuG-CSF in chronic myelogenous leukaemia patients with a poor response to interferon-alpha.
Carella AM; Simonsson B; Link H; Lennard A; Boogaerts M; Gorin NC; Tomas-Martinez JF; Dabouz-Harrouche F; Gautier L; Badri N
Br J Haematol; 1998 Apr; 101(1):111-8. PubMed ID: 9576191
[TBL] [Abstract][Full Text] [Related]
26. High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; Andersson B; Khouri I; Giralt S; Rios MB; Champlin R; Hester J; Deisseroth AB
Bone Marrow Transplant; 1994 Jul; 14(1):57-61. PubMed ID: 7951120
[TBL] [Abstract][Full Text] [Related]
27. Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group.
Axdorph U; Stenke L; Grimfors G; Carneskog J; Hansen J; Linder O; Ljungman P; Löfvenberg E; Malm C; Simonsson B; Turesson I; Vilén L; Udén AM; Björkholm M;
Br J Haematol; 2002 Sep; 118(4):1048-54. PubMed ID: 12199784
[TBL] [Abstract][Full Text] [Related]
28. ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience.
Jerkeman M; Leppä S; Kvaløy S; Holte H
Eur J Haematol; 2004 Sep; 73(3):179-82. PubMed ID: 15287915
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia.
Amadori S; Picardi A; Fazi P; Testi AM; Petti MC; Montefusco E; Mandelli F
Leukemia; 1996 May; 10(5):766-8. PubMed ID: 8656669
[TBL] [Abstract][Full Text] [Related]
30. Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia with different clinical stages.
Gopcsa L; Barta A; Banyai A; Foldi J; Kalasz L; Pajor L; Gidali J; Regeczy N; Paloczi K
Acta Haematol; 2001; 106(3):100-5. PubMed ID: 11713374
[TBL] [Abstract][Full Text] [Related]
31. Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine.
Bauduer F; Delmer A; Blanc MC; Delmas-Marsalet B; Cadiou M; Rio B; Marie JP; Zittoun R
Leuk Lymphoma; 1993 Jun; 10(3):195-200. PubMed ID: 8220118
[TBL] [Abstract][Full Text] [Related]
32. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
[TBL] [Abstract][Full Text] [Related]
33. Quantitative competitive reverse transcriptase-polymerase chain reaction for BCR-ABL on Philadelphia-negative leukaphereses allows the selection of low-contaminated peripheral blood progenitor cells for autografting in chronic myelogenous leukemia.
Corsetti MT; Lerma E; Dejana A; Basta P; Ferrara R; Benvenuto F; Vassallo F; Abate M; Piaggio G; Parodi C; Sessarego M; Li Pira G; Manca F; Carella AM
Leukemia; 1999 Jul; 13(7):999-1008. PubMed ID: 10400414
[TBL] [Abstract][Full Text] [Related]
34. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
Kantarjian HM; Keating MJ; Estey EH; O'Brien S; Pierce S; Beran M; Koller C; Feldman E; Talpaz M
J Clin Oncol; 1992 May; 10(5):772-8. PubMed ID: 1569449
[TBL] [Abstract][Full Text] [Related]
35. Therapy of acute phase chronic myelogenous leukemia with intensive chemotherapy, blood cell autotransplant and cyclosporine A.
Carella AM; Gaozza E; Raffo MR; Carlier P; Frassoni F; Valbonesi M; Lercari G; Sessarego M; Defferrari R; Guerrasio A
Leukemia; 1991 Jun; 5(6):517-21. PubMed ID: 1676080
[TBL] [Abstract][Full Text] [Related]
36. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors influencing feasibility of cytogenetic and molecular analysis in leukapheresis products in chronic myelogenous leukemia patients.
Carrasco M; Sureda A; Martínez C; Carmona M; Altés A; Martín-Henao GA; Aventín A; Sierra J
Ann Hematol; 2002 Dec; 81(12):710-6. PubMed ID: 12483367
[TBL] [Abstract][Full Text] [Related]
38. Preliminary results of stem cell mobilization in chronic myeloid leukemia with a moderate intensity chemotherapy regimen and G-CSF or G-CSF plus IL-3.
Aulitzky WE; Neubauer A; Kolbe K; Schneller F; Busemann C; Schleiermacher E; Peschel C; Siegert W; Huber C; Huhn D
Bone Marrow Transplant; 1996 May; 17 Suppl 3():S67-9. PubMed ID: 8769707
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
[TBL] [Abstract][Full Text] [Related]
40. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD
Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
